1 reports of this reaction
4.3% of all CHLORPHENIRAMINE MALEATE, DEXTROMETHORPHAN HBR reports
#9 most reported adverse reaction
COMA is the #9 most commonly reported adverse reaction for CHLORPHENIRAMINE MALEATE, DEXTROMETHORPHAN HBR, manufactured by ARMY AND AIR FORCE EXCHANGE SERVICE. There are 1 FDA adverse event reports linking CHLORPHENIRAMINE MALEATE, DEXTROMETHORPHAN HBR to COMA. This represents approximately 4.3% of all 23 adverse event reports for this drug.
Patients taking CHLORPHENIRAMINE MALEATE, DEXTROMETHORPHAN HBR who experience coma should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
COMA is moderately reported among CHLORPHENIRAMINE MALEATE, DEXTROMETHORPHAN HBR users, representing a notable but not dominant share of adverse events.
In addition to coma, the following adverse reactions have been reported for CHLORPHENIRAMINE MALEATE, DEXTROMETHORPHAN HBR:
The following drugs have also been linked to coma in FDA adverse event reports:
COMA has been reported as an adverse event in 1 FDA reports for CHLORPHENIRAMINE MALEATE, DEXTROMETHORPHAN HBR. This does not prove causation, but indicates an association observed in post-market surveillance data.
COMA accounts for approximately 4.3% of all adverse event reports for CHLORPHENIRAMINE MALEATE, DEXTROMETHORPHAN HBR, making it a notable side effect.
If you experience coma while taking CHLORPHENIRAMINE MALEATE, DEXTROMETHORPHAN HBR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.